| Literature DB >> 31440249 |
Yuling Shi1,2, Zeyu Chen1,2, Zihan Zhao1,2, Yingyuan Yu1,2, Huayu Fan1,2, Xiaoguang Xu3, Xiaolin Bu4, Jun Gu3.
Abstract
Background: Psoriasis is a chronic immune-mediated inflammatory skin disease, with over-activated interleukin (IL)-17-producing CD4+ T cells (Th17) and repressed regulatory T (Treg) cells. IL-21 is a Th17-related cytokine and plays an important role in the pathogenesis of psoriasis. However, the mechanism by which IL-21 affects the pathogenic progress of psoriasis remains poorly understood.Entities:
Keywords: IL-17A; IL-21; IL-22; Th17 cells; Treg cells; psoriasis
Mesh:
Substances:
Year: 2019 PMID: 31440249 PMCID: PMC6693306 DOI: 10.3389/fimmu.2019.01865
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1IL-21 and IL-21R are highly expressed in the lesional skin of psoriasis patients. (A) IL-21 and IL-21R mRNA expression in the skin of normal people (n = 15) and psoriasis patients (n = 25). (B) Expression levels of mRNA in the skin tissue of normal people (n = 15) and psoriasis patients (n = 25). (C) Western blotting of IL-21 and IL-21R of the skin of normal people (n = 15) and psoriasis patients (n = 25). (D) Immumohistochemical staining of IL-21 and IL-21R of the skin of normal people (n = 15) and psoriasis patients (n = 25). Bar = 75 μm. (E) Immunofluorescence staining of CD4 and IL-21 in skin paraffin sections obtained from normal people (n = 15) and psoriasis patients (n = 25). Bar = 75 μm. Data show means + SD. P-values were determined by unpaired Student's t-test. *P < 0.05, **P < 0.01.
Figure 2IL-21 and IL-21R expression are increased in the peripheral blood of psoriasis patients. (A) IL-21 and IL-21R mRNA expression in PBMCs of normal people (n = 20) and psoriasis patients (n = 58). (B) Expression levels of mRNA in PBMC are shown. Normal (n = 20), Psoriasis (n = 58). (C–D) Flow cytometry of IL-21 and IL-21R expression in CD4+ T cells from normal people (n = 20) and psoriasis patients (n = 58). Data show means + SD. P-values were determined by unpaired Student's t-test. *P < 0.05, **P < 0.01.
Figure 3IL-21 promotes CD4+ T cell proliferation and Th17 cell differentiation, whereas inhibits Treg cell differentiation. (A–B) CFSE labeled CD4+ T cells from normal people (n = 8) and psoriasis patients (n = 12) were treated with or without IL-21 (50 ng/ml) for 3 days. (A) Showed a representative result of flow cytometry of psoriasis patients. (C) RORγt and Foxp3 mRNA expression of CD4+ T cells of normal people (n = 15) and psoriasis patients (n = 30) treated with or without IL-21 (50 ng/ml). (D–E) The proportion of Th17 cells (CD4+ IL-17A+ cells) in CD4+ T cells of normal people (n = 15) and psoriasis patients (n = 30) treated with or without IL-21 (50 ng/ml) for 3 days. (D) Showed a representative result of FACS of psoriasis patients. (F–G) The proportion of Treg cells (CD4+, CD25+, and Foxp3+ cells) in CD4+ T cells of normal people (n = 15) and psoriasis patients (n = 30) treated with or without IL-21 (50 ng/ml) for 3 days. (F) Showed a representative FACS result of normal people. Data show means + SD. P-values were determined by paired Student's t-test. *P < 0.05, **P < 0.01, ****P < 0.0001.
Figure 4IL-21 increases Th17-related cytokines expression and regulates Treg-related cytokines expression in CD4+ T cells. (A) IL-17A and IL-22 mRNA expression of CD4+ T cells from normal people (n = 15) and psoriasis patients (n = 30) treated with or without IL-21 (50 ng/ml) for 3 days. (B) IL-17A and IL-22 were quantified in the supernatant of CD4+ T cells from normal people (n = 15) and psoriasis patients (n = 30) treated with or without IL-21 (50 ng/ml) for 3 days by ELISA. (C–D) The expression of TGF-β of Treg cells in CD4+ T cells of normal people (n = 15) and psoriasis patients (n = 30) treated with or without IL-21 (50 ng/ml) for 3 days. (C) Showed a representative FACS result of normal people. (E–F) The expression of IL-10 of Treg cells in CD4+ T cells of normal people (n = 15) and psoriasis patients (n = 30) treated with or without IL-21 (50 ng/ml) for 3 days. (E) Showed a representative FACS result of normal people. (G) IL-10 was quantified in the supernatant of CD4+ T cells from normal people (n = 15) and psoriasis patients (n = 30) treated with or without IL-21 (50 ng/ml) for 3 days by CBA. Data show means + SD. P-values were determined by paired Student's t-test. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 5The proportion of Treg cells is negatively correlated with Th17 cells. (A–B) Proportion of Th17 cells in CD4+ cells of PBMCs from normal people (n = 20) and psoriasis patients (n = 58). (C–D) Proportion of CD25+Foxp3+ in CD4+ cells of PBMCs from normal people (n = 20) and psoriasis patients (n = 58). (E) Correlation between the proportion of Th17 cells and Treg cells of CD4+ cells of all participants (n = 78). (F–G) Proportion of Th1 cells in CD4+ cells of PBMCs from normal people (n = 20) and psoriasis patients (n = 58). (H) Correlation between the proportion of Th17 cells and Th1 cells of CD4+ cells of all participants (n = 78). Data show means + SD. P-values were determined by unpaired Student's t-test. **P < 0.01.
Figure 6Summary of IL-21 actions in psoriatic inflammation. Under the psoriatic inflammatory microenvironment, CD4+ T cells secret abundant IL-21. Then IL-21 acts on CD4+ T cells via IL-21R to increase RORγt expression and decrease Foxp3 expression, resulting in imbalance of Th17 and Treg cells and increased expression of IL-17A and IL-22, further aggravating the inflammatory microenvironment of psoriasis.